MP0250-a dual inhibitor of VEGF and HGF - plus bortezomib plus dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM)

被引：0
|
作者：
Raab, M. S. [1 ]
Ria, R. [2 ]
Schlenzka, J. [1 ]
Krahnke, T. [3 ]
Haunschild, J. [4 ]
Herrmann, F. [4 ]
Fiedler, U. [5 ]
Dawson, K. [6 ]
Stumpp, M. T. [7 ]
Mehr, K. Tadjalli [4 ]
Harstrick, A. [4 ]
Vacca, A. [2 ]
Goldschmidt, H. [1 ]
机构：
[1] Heidelberg Univ Hosp, Dept Haematol Oncol & Rheumatol, Heidelberg, Germany
[2] Univ Bari, Med Sch, Dept Biomed Sci & Human Oncol, Sect Internal Med, Bari, Italy
[3] Gogitars GmbH, Biostat, Heidelberg, Germany
[4] Mol Partners AG, Clin Dev, Schlieren, Switzerland
[5] Mol Partners AG, Preclin, Schlieren, Switzerland
[6] Mol Partners AG, Preclin Toxicol, Schlieren, Switzerland
[7] Mol Partners AG, CSO, Schlieren, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1041TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
    Deng, Li-Juan
    Zhou, Ke-Shu
    Liu, Li-Hong
    Zhang, Ming-Zhi
    Li, Zhi-Ming
    Ji, Chun-Yan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Su-Jun
    Zhang, Hui-Lai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Hai-Yan
    Cao, Jun-Ning
    Zhu, Zun-Min
    Hu, Jian-Da
    Zhang, Wei
    Jing, Hong-Mei
    Ding, Kai-Yang
    Zhang, Xiang-Yang
    Zhao, Ren -Bin
    Zhang, Bin
    Tian, Ya -Min
    Song, Yong-Ping
    Song, Yu-Qin
    Zhu, Jun
    BLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357
  • [32] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Radhakrishnan
    BLOOD, 2012, 120 (21)
  • [33] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
    Richardson, Paul G.
    Oriol, Albert
    Beksac, Meral
    Liberati, Anna Marina
    Galli, Monica
    Schjesvold, Fredrik
    Lindsay, Jindriska
    Weisel, Katja
    White, Darrell
    Facon, Thierry
    Miguel, Jesus Son
    Sunami, Kazutaka
    O'Gorman, Peter
    Sonneveld, Pieter
    Robak, Pawel
    Semochkin, Sergey
    Schey, Steve
    Yu, Xin
    Doerr, Thomas
    Bensmaine, Amine
    Biyukov, Tsvetan
    Peluso, Teresa
    Zaki, Mohamed
    Anderson, Kenneth
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2019, 20 (06): : 781 - 794
  • [34] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
    Lan, Chunyan
    Shen, Jingxian
    Wang, Yin
    Li, Jundong
    Liu, Zhimin
    He, Mian
    Cao, Xinping
    Ling, Jiayu
    Huang, Jiaming
    Zheng, Min
    Zou, Guorong
    Yan, Haowen
    Liu, Qing
    Yang, Fan
    Wei, Wei
    Deng, Yanhong
    Xiong, Ying
    Huang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)
  • [35] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL
    Xu, Xiaoting
    Huan, Jian
    Miao, Hui
    Wang, Hao
    Wang, Yue
    Zhu, Hongyu
    Jiang, Jun
    Zhou, Juying
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384
  • [36] Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial.
    Lan, Chunyan
    Huang, Xin
    Shen, Jing-Xian
    Wang, Yin
    Xiong, Ying
    Li, Jundong
    Cao, Xinping
    Deng, Yanhong
    He, Mian
    Zou, Guorong
    Wang, Xiaodi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Weller, Edie
    Jagannath, Sundar
    Avigan, David E.
    Alsina, Melissa
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    McKenney, Mary
    Delaney, Carol
    Mitsiades, Constantine S.
    Hideshima, Teru
    Dalton, William
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5713 - 5719
  • [38] Trial in progress: an open-label, multicenter, phase 1 study for IGM-2644 in participants with relapsed and/or refractory multiple myeloma (RRMM)
    Funke, Roel
    Schade, Henning
    Berdeja, Jesus
    Li, Keyu
    Kotturi, Maya
    Hernandez, Genevive
    Guan, Yinghui
    Deodhar, Malavika
    Durant, Dominique
    Takimoto, Chris
    Manley, Thomas
    Hart, Kevin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S60 - S61
  • [39] Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study
    Grammatico, Sara
    Bringhen, Sara
    Vozella, Federico
    Siniscalchi, Agostina
    Boccadoro, Mario
    Petrucci, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2738 - 2740
  • [40] Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Hungria, Vania T. M.
    Yoon, Sung-Soo
    Beksac, Meral
    Dimopoulos, Meletios A.
    Elghandour, Ashraf
    Jedrzejczak, Wieslaw W.
    Guenther, Andreas
    Nakorn, Thanyaphong Na
    Siritanaratkul, Noppadol
    Schlossman, Robert L.
    Hou, Jian
    Moreau, Philippe
    Lonial, Sagar
    Lee, Jae Hoon
    Einsele, Hermann
    Sopala, Monika
    Bengoudifa, Bourras-Rezki
    Corrado, Claudia
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
12345